What is Amfora?
Amfora operates at the intersection of biotechnology and agricultural science, specializing in the genetic enhancement of crops to improve their nutritional density. By focusing on the fundamental biology of plants, the company seeks to provide scalable solutions for food security and human wellness. Its market position is defined by its ability to integrate advanced life sciences with traditional agricultural practices, making it a critical player in the burgeoning ag-tech sector. The company's core competency lies in its ability to optimize crop traits, thereby creating value for both producers and consumers in a global market increasingly concerned with the nutritional quality of food sources.
How much funding has Amfora raised?
Amfora has raised a total of $12M across 2 funding rounds:
Series A
$5M
Series B
$7M
Series A (2017): $5M with participation from Commonwealth Scientific Industrial Research Organization (CSIRO) and Spruce Capital
Series B (2021): $7M led by Spruce Capital Partners, BayWa, and Leaps by Bayer
Key Investors in Amfora
Spruce Capital Partners
A venture capital management firm based in San Francisco that focuses on investing in and building innovative companies in the Ag, Nutrition, and Industrial Life Sciences sectors.
BayWa
A diversified global company headquartered in Germany with extensive operations across the agricultural, construction, and energy industries.
Leaps by Bayer
The venture capital arm of Bayer, focusing on breakthrough technologies and life sciences innovations that have the potential to solve some of the world's toughest challenges.
What's next for Amfora?
With the recent influx of capital, Amfora is poised to enter a critical phase of commercialization and operational expansion. The strategic roadmap likely involves scaling its proprietary crop development platform and deepening its partnerships within the global agricultural supply chain. As the company moves beyond the development stage, the focus will shift toward regulatory milestones and the deployment of its enhanced crop varieties into broader markets. Investors are closely monitoring how this capital will be utilized to solidify Amfora's competitive advantage in the high-growth biotechnology landscape, particularly as the firm seeks to address the growing demand for sustainable and nutrient-rich food solutions.
See full Amfora company page
